Cargando…

Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorramdelazad, Hossein, Kazemi, Mohammad Hossein, Azimi, Maryam, Aghamajidi, Azin, Mehrabadi, Ali Zarezadeh, Shahba, Faezeh, Aghamohammadi, Nazanin, Falak, Reza, Faraji, Fatemeh, Jafari, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124632/
https://www.ncbi.nlm.nih.gov/pubmed/35618037
http://dx.doi.org/10.1016/j.ejphar.2022.175051
_version_ 1784711777974484992
author Khorramdelazad, Hossein
Kazemi, Mohammad Hossein
Azimi, Maryam
Aghamajidi, Azin
Mehrabadi, Ali Zarezadeh
Shahba, Faezeh
Aghamohammadi, Nazanin
Falak, Reza
Faraji, Fatemeh
Jafari, Reza
author_facet Khorramdelazad, Hossein
Kazemi, Mohammad Hossein
Azimi, Maryam
Aghamajidi, Azin
Mehrabadi, Ali Zarezadeh
Shahba, Faezeh
Aghamohammadi, Nazanin
Falak, Reza
Faraji, Fatemeh
Jafari, Reza
author_sort Khorramdelazad, Hossein
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation.
format Online
Article
Text
id pubmed-9124632
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-91246322022-05-23 Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 Khorramdelazad, Hossein Kazemi, Mohammad Hossein Azimi, Maryam Aghamajidi, Azin Mehrabadi, Ali Zarezadeh Shahba, Faezeh Aghamohammadi, Nazanin Falak, Reza Faraji, Fatemeh Jafari, Reza Eur J Pharmacol Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation. Elsevier B.V. 2022-07-15 2022-05-23 /pmc/articles/PMC9124632/ /pubmed/35618037 http://dx.doi.org/10.1016/j.ejphar.2022.175051 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Khorramdelazad, Hossein
Kazemi, Mohammad Hossein
Azimi, Maryam
Aghamajidi, Azin
Mehrabadi, Ali Zarezadeh
Shahba, Faezeh
Aghamohammadi, Nazanin
Falak, Reza
Faraji, Fatemeh
Jafari, Reza
Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title_full Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title_fullStr Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title_full_unstemmed Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title_short Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
title_sort type-i interferons in the immunopathogenesis and treatment of coronavirus disease 2019
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124632/
https://www.ncbi.nlm.nih.gov/pubmed/35618037
http://dx.doi.org/10.1016/j.ejphar.2022.175051
work_keys_str_mv AT khorramdelazadhossein typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT kazemimohammadhossein typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT azimimaryam typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT aghamajidiazin typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT mehrabadializarezadeh typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT shahbafaezeh typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT aghamohammadinazanin typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT falakreza typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT farajifatemeh typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019
AT jafarireza typeiinterferonsintheimmunopathogenesisandtreatmentofcoronavirusdisease2019